From: Next generation of immune checkpoint inhibitors and beyond
Category | Target | Drug | Trial | Phase | Type of tumor | Clinical efficacy | Safety | Comments |
---|---|---|---|---|---|---|---|---|
Inhibitory immune checkpoint targets | LAG-3 (CD223) | LAG525 (IMP701) | NCT02460224 | I/II | Advanced malignancies | 11/121 patients in the combination group achieved PR 1 patient had a CR | DLTs occurred in 4/121 patients included grade 3 and 4 pneumonitis, acute kidney injury, and autoimmune hepatitis | With or without spartalizumab |
 |  |  | NCT03365791 | II | Solid or hematologic malignances | DCR for neuroendocrine tumors (86%), diffuse large B cell lymphoma (43%), and small cell lung cancer (27%) | 11/72 patients had grade 3 or 4 AEs including dyspnea, fatigue, and poor appetite | In combination with spartalizumab |
 |  | REGN3767 (R3767) | NCT03005782 | I | Solid or hematologic malignances | Monotherapy group: ORR 0% and DCR 48% with 12 SD Combination group: ORR 5% and DCR was 31% with 2 PR and 11 SD 2/12 PR and 6 SD in the group crossed over from monotherapy to the combination | 1/67 DLT in the combination group (G4 CK elevation + G3 myasthenic syndrome + G1 elevation of troponin | Alone or in combination with cemiplimab |
 |  | BI 754,091 | NCT03156114, NCT03433898, NCT03780725 | I | Advanced or metastatic solid tumors | Not reported | 21/321 DLTs, particularly infusion-related reactions (n = 6). Serious AEs: 77/321 (27%): pleural effusion (n = 6), deep venous thrombosis (n = 4), cardiac tamponade (n = 1), and acute kidney injury (n = 1) | Used in combination with anti-PD-1 therapy |
 |  |  | NCT03697304 | II |  |  |  |  |
 |  | Tebotelimab (MGD013) | NCT03219268 | I | Advanced or metastatic solid or hematologic malignancies | Dose escalation (n = 29): ORR 10% and DCR 55% with 3 confirmed PR, 1 unconfirmed PR, and 13 SD Expansion cohort (n = 41): ORR 7%, DCR 59% with 3 PR, and 21 SD | 2/207 DLTs: immune-mediated hepatitis and increased lipase | Alone or in combination with margetuximab (for patients who had expression of HER2 on their tumors) |
 |  | Eftilagimod alpha (IMP321) | NCT02676869 | I | Advanced melanoma | 1/18 CR | No DLTs reported | Used with pembrolizumab |
 |  |  | NCT03252938 | I | Advanced solid tumors | ORR 17% and DCR 33% with 1/6 PR, 1/6 SD, and 4/6 PD | No DLTs reported | Used with avelumab |
 |  |  | NCT03625323 | II | Advanced or metastatic NSCLC and HNSCC | ORR 47% and DCR 82% with 8/17 PR and 6/17 SD | Most common toxicities included cough (31%), fatigue (19%), and diarrhea (15%) | Used with pembrolizumab |
 |  | FS118 | NCT03440437 | I | Advanced solid tumors |  |  | Ongoing |
 | TIM-3 | MBG453 | NCT02608268 | I/II | Advanced solid tumors | ORR in the monotherapy group was 0% and DCR was 29% with 25/87 SD ORR in the combination group was 5% and DCR was 44% with 4/86 PR and 34/86 SD | One DLT in combination cohort (grade 4 MG) 11% developed grade 3 or 4 AEs in the combination cohort | Combined with spartalizumab |
 |  | Sym023 | NCT03489343 | I | Advanced solid tumors and lymphomas | – | – | No results available |
 |  | TSR-022 | NCT02817633 | I | Advanced solid tumors | – | – | Ongoing |
 | B7-H3 and B7-H4 | MGC018 | NCT03729596 | I/II | Advanced solid tumors | ORR 0% and DCR 15% with 3/20 SD | 1 DLT: grade 4 neutropenia 3 serious AEs: pneumonitis, gastroenteritis, stasis dermatitis | Used as monotherapy |
 |  | FPA150 | NCT03514121 | I | B7-H4 positive solid malignancies | ORR 3% and DCR 38% with 1/29 PR and 10/29 SD | No DLTs or grade 4/5 toxicities were reported | Used as monotherapy |
 | A2aR | EOS100850 | NCT02740985 | I | Advanced solid tumors | ORR 0% and a DCR of 29% with 6/21 SD | No DLTs and no grade 3 or 4 AEs | Used as monotherapy. First in human |
 |  | AB928 | NCT03719326 NCT03720678 NCT03629756 | I | Advanced solid tumors | ORR 4% and DCR of 27% with 1/26 PR and 6/26 SD | 1 DLT: grade 1 rash 6 patients with grade 3 or 4 AEs: fatigue, nausea, and cytopenias | Used in combination with standard chemotherapy or anti-PD-1 therapy |
 | CD73 | CPI-006 | NCT03454451 | I | Advanced solid tumors | 1 patient (monotherapy) with metastatic CRPC: substantial reduction in the size of a target lesion after only 5 cycles, sustained at the time of cutoff | No DLTs reported | Used as monotherapy or in combination with an anti-A2aR agent (CPI-444) |
 | NKG2A | Monalizumab | NCT03088059 | II | Platinum-resistant, recurrent or metastatic, HNSCC | PFS: 7.4 weeks Median OS: 27.7 weeks ORR 0%, DCR 22% with 6/27 SD | No DLTs reported | Used as monotherapy |
 |  |  | NCT02643550 | II | Platinum-resistant, recurrent or metastatic, HNSCC | ORR 20% DCR 58% with 8/40 PR 15/40 SD | No DLTs reported | Used in combination with cetuximab |
 | PVRIG/ PVRL2 | COM701 | NCT03667716 | I | Advanced Solid tumors | DCR 57% (16/28 patients) No CRs 1/16 PR in the monotherapy group 1/12 unconfirmed PR in the combination group | No DLTs reported | Used as monotherapy and in combination with nivolumab |
Inhibitory targets beyond immune checkpoints | CEACAM1 | CM24 | NCT02346955 | I | Advanced or recurrent solid tumors | ORR of 0% and a DCR of 30% with 8/27 SD Median OS 4 months (lower dose), and 6 months (higher dose) | No DLTs 4 individuals with grade 3–4 GGT elevation | Used as monotherapy |
 | CEACAM 5/6 | NEO-201 | NCT03476681 | I | Advanced solid tumors | ORR 0% and DCR 33% with radiological SD in 3/9 patients | No DLTs reported | Used as monotherapy |
 | FAK | Defactinib | NCT02546531 | I | Advanced pancreatic adenocarcinoma | Escalation cohort (n = 8): ORR 13% and DCR 50% with 1 PR, 3 SD, and 4 PD Expansion cohort (= 20): ORR 5% and DCR 60% with 1 PR, 11 SD, 7 PD and 1 non-evaluable response | No DLTs were seen Most common grade 1 and 2 AEs included fatigue, anorexia, nausea, and vomiting | Used in combination with pembrolizumab and gemcitabine |
 | CCL2/ CCR2 | PF-04136309 | NCT02732938 | I | Metastatic pancreatic adenocarcinoma | ORR 23.8%, DCR 38% with 0/21 CR, 5/21 confirmed PR, 1/21 unconfirmed PR, and 3/21 SD | DLTs: dysesthesia, hypokalemia, and hypoxia 24% pulmonary toxicities including 3 patients with grade 3 pneumonitis, 1 grade 4 hypoxia, and 1 grade 5 pneumonia | Used in combination with nab-paclitaxel and gemcitabine |
 | LIF | MSC-1 | NCT03490669 | I | Advanced solid tumors | DCR 22% with 9/41 SD lasting > 16 weeks | No DLTs reported | Used as monotherapy |
 | CD47/ SIRP | Hu5F9-G4 (5F9) | NCT02216409 | I | Advanced Solid tumors | ORR ~ 5% DCR 19% with 2/43 PR (ovarian and fallopian tube cancers) and 6/43 SD (CRC) | AEs occurred with higher doses. These included constitutional symptoms (50%), headache (34%), anemia (39%), and lymphopenia (28%) | Used as monotherapy |
 |  |  | NCT02953509 | I/II | Relapsed and refractory NHL | CRR 21% ORR 49% with 16/75 CR and 21/75 PR | DLTs 4% (no specifics provided) | Combined with rituximab |
 |  | ALX148 | NCT03013218 | I | Advanced solid tumors or refractory NHL | ICI-naïve HNSCC: ORR 40% (4/10), median PFS 4.6 months, and median OS not reached after 14 months of follow-up Non-ICI-naïve HNSCC: ORR 0%, median PFS 2 months, median OS 7.4 months ALX148 + trastuzumab in gastric/gastroesophageal cancers (n = 20): ORR 20%, median PFS 2.2 months, and median OS 8.1 months Monotherapy (n = 25): DCR 16% with 4/25 SD | 2 DLTs: neutropenia with infection and thrombocytopenia with a significant bleed 1 grade 5 (fatal) toxicity under investigation Most AEs (66%) were low grade | Used in monotherapy agent or with pembrolizumab, trastuzumab, rituximab, ramucirumab, 5FU, paclitaxel, or cisplatin |
 |  | TTI-662 | NCT03530683 | I | Relapsed or refractory lymphomas | 1 patient (DLBCL) with 5 prior lines of therapy achieved a PR by week 8 and a CR by week 36 | No DLTs | Used as monotherapy |
 |  | RRx-001 | NCT02518958 | I | Advanced solid malignancies or lymphomas | ORR 25%, DCR 67% with 3/12 PR, 5/12 SD, and 3/12 PD | No DLTs reported 1 patient discontinued therapy due to pneumonitis | Used in combination with nivolumab |
 | CSF-1 (M-CSF)/ CSF-1R | Lacnotuzumab (MCS110) | NCT02807844 | I/II | Advanced malignancies | DCR 27% 3/48 had pancreatic cancer: 1 PR, and 2 SD lasting > 300 days | No DLTs reported | Used in conjunction with spartalizumab |
 |  | LY3022855 | NCT02265536 | I | Metastatic BC and metastatic CRPC | BC (n = 22): DCR 23% with 5/22 SD. 2 of these had a response that lasted > 9 months CRPC (n = 7): ORR 0% and DCR 43% with 3/7 SD lasting up to 4 months | No DLTs reported | Used as monotherapy |
 |  | SNDX-6352 | NCT03238027 | I | Advanced solid tumors | DCR 13% with 4/32 SD that lasted > 4 months | 2 DLTs, one grade 3 fatigue and one grade 3 pneumonitis | Used as monotherapy and in combination with durvalumab |
 |  | Emactuzumab (RG7155) | NCT01494688 | I | Advanced solid tumors | Monotherapy (n = 99): ORR 0% and DCR 13% with 13/99 SD Combination (n = 54): ORR 7% DCR 50% with 4/54 PR 23/54 SD | No DLTs in the monotherapy, 2 DLTs in the combination: one grade 4 hypokalemia and one grade 3 hemorrhagic enterocolitis One grade 5 AE: bowel perforation | Used as monotherapy or in combination with paclitaxel |
 |  | Pexidartinib (PLX3397) | NCT01525602 | I | Advanced solid tumors | ORR 16%, DCR 50%, PD rate 45% with 1/38 CR, 5/38 PR, 13/38 SD, and 17/38 PD | 2 DLTs: one grade 3 atrial fibrillation and one grade 3 hypophosphatemia | Used in combination with paclitaxel |
 |  |  | NCT02777710 | I | Advanced or metastatic pancreatic adenocarcinoma or CRC | ORR 0% and DCR 21% with 4/19 SD | 2 DLTs: both transaminase elevation, one with hyperbilirubinemia | Used with durvalumab |
 |  |  | NCT02734433 | I | Asian patients with symptomatic, advanced solid malignancies | DCR 67% with 1/11 PR and 4/11 SD | 5 patients experienced at least one grade 3 or 4 AE: elevated transaminases and anemia | Monotherapy |
 | IL-1 and IL-1R3 (IL-1RAP) | CAN04 | NCT03267316 | I | Advanced or metastatic NSCLC, CRC, BC, or pancreatic adenocarcinoma | DCR 45% with 9/22 SD including 2 whose response lasted > 4 months | No DLTs or grade 4–5 AEs reported | Used as monotherapy |
 |  | Canakinumab (ACZ885) | NCT03968419 | II | Early-stage NSCLC | – | – | Ongoing |
 | IL-8 | BMS-986253 | NCT02536469 | I | Advanced solid tumors | ORR 0% and DCR 73% with 11/15 SD and 4/15 PD | No DLTs reported | Used as monotherapy |
 |  |  | NCT03400332 | I/II | Advanced solid tumors | – | – | Ongoing |
 | SEMA4D | Pepinemab (VX15/2503) | NCT03268057 | I/II | Advanced-stage NSCLC | Immunotherapy-naïve (n = 21): ORR 24% and DCR 81% with 5/21 PR and 12/21 SD Immunotherapy-refractory (n = 29): ORR was 7% and DCR was 59% with 2 patients achieving PR and 15 SD | No DLTs reported | Used in combination with avelumab |
 | Ang-2 | Trebananib | NCT03239145 | I | Advanced solid tumors | DCR 33% and ORR 7% with 1/15 PR and 4/15 SD Median time to progression: 2.6 months OS: 11.4 months | No DLTs and no grade 3 or 4 AEs | Used in combination with pembrolizumab |
 | CLEVER-1 | FP-1305 | NCT03733990 | I/II | Advanced solid tumors | ORR 3% and DCR 27% with 2/30 PR, 6/30 SD, and 22/30 PD | No DLTs reported | Used as monotherapy |
 | Axl | Enapotamab vedotin (EnaV) | NCT02988817 | I | Advanced solid tumors | ORR 6%, DCR 55% with 3/47 PR and 26/47 SD | 6 DLTs: constipation, vomiting, GGT elevation, febrile neutropenia, and diarrhea | First-in-human clinical trial. Used as monotherapy |
 | Phosphatidylserine | Bavituximab | NCT01264705 | II | Advanced, unresectable HCC | ORR 5%, DCR 58% with 2/38 PR and 20/38 SD | No DLTs or grade 4–5 AEs reported | Used in combination with sorafenib |